The Drug Susceptibility of Aspergillus Species Isolated from the Patients with Onychomycosis to Itraconazole, Voriconazole, and Amphotericin B

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Medical Parasitology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Associate Professor, Department of Medical Parasitology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Professor, Department of Medical Parasitology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Associate Professor, Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Medical Parasitology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Nowadays, the prevalence of onychomycosis caused by non-dermatophyte molds is increasing. As Aspergillus is the most common etiologic agents of the disease, this study was performed to evaluate the susceptibility of clinical isolates of Aspergillus as the cause of onychomycosis to itraconazole, voriconazole, and amphotericin B.Methods: This cross-sectional study was performed on 50 Aspergillus strains isolated from the patients with onychomycosis referred to diagnostic laboratories of university hospitals in Mashhad, Iran. According to the phenotypic and molecular analysis of Aspergillus isolates, the most frequent species was Aspergillus flavus (A. flavus) with 34 cases. The drug susceptibility test was performed according to Clinical and Laboratory Standards Institute-M38-A2 (CLSI-M38-A2) protocol, and the minimum inhibitory concentration (MIC) of the drugs was determined.Findings: From 50 patients with dystrophic nails, 13 were men and 37 were women. 15 patients had fungal infection of fingernails, and 33 patients had fungal infection on toenails; 2 patients had both infections of finger and toe nails. 14.7% of A. flavus isolates with MIC > 2 μg/ml to amphotericin B were considered as resistant clinical isolates. The sensitivity to itraconazole and voriconazole was 100%. MIC90 of amphotericin B, itraconazole, and voriconazole were obtained by broth microdilution method for A. flavus species as 4, 0.25, and 1 μg/ml, respectively. Significant difference was observed in MIC between itraconazole and amphotericin B (P < 0.050).Conclusion: All Aspergillus species are susceptible to itraconazole and voriconazole, and these two drugs are more effective than amphotericin B on Aspergillus species. Due to the different susceptibility of these species to antifungal agents, it is necessary to perform drug susceptibility testing in order to select the appropriate drug.

Keywords

References

  1. Midgley G, Moore MK. Nail infections. Dermatol Clin 1996; 14(1): 41-9.
  2. Nouripour-Sisakht S, Mirhendi H, Shidfar MR, Ahmadi B, Rezaei-Matehkolaei A, Geramishoar M, et al. Aspergillus species as emerging causative agents of onychomycosis. J Mycol Med 2015; 25(2): 101-7.
  3. Ghasemi Z, Falahati M, Sadri M, Farehyar S, Nami S, Nozari S, et al . Report of 34 cases of saprophytic fungi isolated from dystrophic nails of patients referred to Razi Hospital (2010-2011). Razi J Med Sci 2012; 18(92): 8-14. [In Persian].
  4. Kaur R, Kashyap B, Bhalla P. Onychomycosis--epidemiology, diagnosis and management. Indian J Med Microbiol 2008; 26(2): 108-16.
  5. Elewski BE. Onychomycosis: Pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11(3): 415-29.
  6. Hojatinia H, Sabokbar A. Sensitivity determination of Aspergilus Flavus to Itraconazol, Voriconazol and Caspofungin. New Cellular and Molecular Biotechnology Journal 2016; 6(22): 51-8. [In Persian].
  7. Bongomin F, Batac CR, Richardson MD, Denning DW. A review of onychomycosis due to aspergillus species. Mycopathologia 2018; 183(3): 485-93.
  8. Hoseinnejad A, Hedayati MT, Moazeni M, Taghizadeh Armaki M, Abastabar M, Jabari Amiri MR, et al. Antifungal susceptibility testing of 90 clinical and environmental isolates of Aspergillus flavus to voriconazole and itraconazole. J Mazandaran Univ Med Sci 2016; 25(133): 91-9. [In Persian].
  9. Ahmadi B, Rezaei S, Hashemi F, Zareei M, Deli H, Hashemi SJ. The use of PCR to diagnose onychomycosis caused by non-dermatophytic molds. Payavard Salamat 2015; 9(4): 388-99. [In Persian].
  10. Hashemi SJ, Gerami M, Zibafar E, Daei M, Moazeni M, Nasrollahi A. Onychomycosis in Tehran: Mycological study of 504 patients. Mycoses 2010; 53(3): 251-5.
  11. Hashemi SJ, Zaini F, Daie R, Zibafar E, Zakeri MA. In-vitro susceptibility of Aspergillus species isolated from cutaneous and visceral lesions to antifungal agents. Tehran Univ Med J 2011; 69(2): 83-91. [In Persian].
  12. Tupaki-Sreepurna A, Jishnu BT, Thanneru V, Sharma S, Gopi A, Sundaram M, et al. An assessment of in vitro antifungal activities of efinaconazole and itraconazole against common non-dermatophyte fungi causing onychomycosis. J Fungi (Basel) 2017; 3(2): 20.
  13. Nasrolahiomran A. Evatuation of drug susceptibility of Aspergillus species isolated from ICU of hospitals in invitro. J Ilam Univ Med Sci 2018; 25(6): 130-40. [In Persian].
  14. Bakhshi T, Salari S, Naseri A, Esfandiarpour I, Mohammadi MA, Ghasemi Nejad Almani P. Molecular identification of candida species in patients with candidiasis in Birjand, Iran, using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. J Isfahan Med Sch 2016; 33(359): 1986-93. [In Persian].
  15. Diba K, Kordbacheh P, Mirhendi SH, Rezaie S, Mahmoudi M. Identification of Aspergillus species using morphological characteristics. Pak J Med Sci 2007; 23(6): 867-72.
  16. McClenny N. Laboratory detection and identification of Aspergillus species by microscopic observation and culture: The traditional approach. Med Mycol 2005; 43(Suppl 1): S125-S128.
  17. Samson RA, Visagie CM, Houbraken J, Hong SB, Hubka V, Klaassen CH, et al. Phylogeny, identification and nomenclature of the genus Aspergillus. Stud Mycol 2014; 78: 141-73.
  18. Moghaddami M, Shidfar MR. A study of onychomycosis in Tehran. Med J Islam Repub Iran. 1989; 3(3-4): 143-9.
  19. Zeini F, Mehbod ASA, Emami M. Comprehensive medical mycology. 3rd ed. Tehran, Iran: University of Tehran Publications; 2009. p. 154. [In Persian].
  20. Zalacain A, Obrador C, Martinez JP, Vinas M, Vinuesa T. Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain. Med Mycol 2011; 49(5): 495-9.
  21. Kulkarni SS, Bhakre JB, Damle AS. In vitro susceptibility testing of four antifungal drugs against fungal isolates in onychomycosis. Int J Res Med Sci 2018; 6(8): 2774-80.
  22. Tsang CC, Hui TW, Lee KC, Chen JH, Ngan AH, Tam EW, et al. Genetic diversity of Aspergillus species isolated from onychomycosis and Aspergillus hongkongensis sp. nov., with implications to antifungal susceptibility testing. Diagn Microbiol Infect Dis 2016; 84(2): 125-34.
  23. Oz Y, Ozdemir HG, Gokbolat E, Kiraz N, Ilkit M, Seyedmousavi S. Time-kill kinetics and in vitro antifungal susceptibility of non-fumigatus Aspergillus species isolated from patients with ocular mycoses. Mycopathologia 2016; 181(3-4): 225-33.
  24. Al-Wathiqi F, Ahmad S, Khan Z. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait. BMC Infect Dis 2013; 13: 126.
  25. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: Epidemiology and detection. Med Mycol 2011; 49(Suppl 1): S90-S95.
Journal of Isfahan Medical School
Volume 38, Issue 577 - Serial Number 577
May and June 2020
Pages 367-375

Files

History

  • Receive Date: 18 April 2020
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics